HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Promise of biosimilars tempered by complexity, caution
-
- FDA adds contraindication to dolasetron mesylate injection
- FDA declines approval of ticagrelor without additional information
- FDA rules to remove breast cancer indication from bevacizumab
- Chondrosarcoma of the petroclival synchondrosis Munir Ghesani, MD, FACNM; Daniel E. Meltzer, MD; Arzu Buyuk, MD; Ali Noor, MD; Yinghua Pang, MD
- B-cell count gold standard for diagnosing CLL
- Endometrial cancer detected with transvaginal ultrasound in postmenopausal women
- Genetic, immunologic patterns may offer insight into second malignancy etiologies
- Questions remain for more aggressive ovarian cancer screening
-
- Two-year rituximab maintenance regimen may improve outcomes for patients with follicular lymphoma
- Working group offers recommendations for preventing renal impairment in patients with multiple myeloma
- AZURE results may contradict ABCSG-12 results for zoledronic acid use
- G-CSF associated with more live births in women with severe neutropenia
- Pertuzumab, trastuzumab gain further credibility as adjuvant therapies
- Rivaroxaban reduced incidence of DVT, major bleeding risk